Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
TCBPW TC BIOPHARM (HOLDINGS) PLC C/WTS 08/02/2027 (TO PUR ADS)
0.140+0.010+7.69%
Trading Session
01/31 10:29 ET
High
0.140
Open
0.140
Turnover
1.40K
Low
0.140
Pre Close
0.130
Volume
10.00K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division
Will oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical
TC BioPharm to Host Shareholder Update Call
TC BioPharm Receives Notice Of Non-compliance With NASDAQ's Listing Rule 5550(b)(1)
TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), has received written notification from the listing qualifications staff of the Nasdaq Stock Market, LLC ("Nasd
TC BioPharm Announces Strategic Collaboration To Advance Gamma Delta T Cells In Oncology
Endeavor to focus on expanding understanding of gamma-delta T cells in oncological settings EDINBURGH, Scotland, Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company
TC BioPharm Announces Closing of $7.35 Million Private Placement
TC BioPharm Announces $7.35 Million Private Placement
TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating Its Lead Compound, OmnImmune, In Patients With Acute Myeloid Leukemia
3 Patients Dosed in 5 Patient Safety CohortEDINBURGH, Scotland, Nov. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage
TC BioPharm Receives MHRA Approval For 18-Month Extrapolated Shelf-Life Of Allogeneic Cell Therapy Product, OmnImmune
EDINBURGH, Scotland, Sept. 13, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform
TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
EDINBURGH, Scotland, Aug. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer tre
TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022"
PRNewswire 8-Jul-2022 8:30 AMManagement will Participate in Fireside Chat on TC BioPharm's Journey as a Successful CGT Startup on July 13, 2022 EDINBURGH, Scotland., July 8, 2022 /PRNewswire/ -- TC B
Company Overview
More
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.
CEO： Mr. Bryan Kobel
Market： NASDAQ
Listing Date： 02/11/2022
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet